General Information of the Protein
Protein ID
PT01159
Protein Name
Receptor tyrosine-protein kinase erbB-4
Secondarily
Protein Name
Proto-oncogene-like protein c-ErbB-4
Tyrosine kinase-type cell surface receptor HER4
p180erbB4
s80HER4
Gene Name
ERBB4
Secondarily
Gene Name
HER4
Sequence
MKPATGLWVWVSLLVAAGTVQPSDSQSVCAGTENKLSSLSDLEQQYRALRKYYENCEVVMGNLEITSIEHNRDLSFLRSVREVTGYVLVALNQFRYLPLENLRIIRGTKLYEDRYALAIFLNYRKDGNFGLQELGLKNLTEILNGGVYVDQNKFLCYADTIHWQDIVRNPWPSNLTLVSTNGSSGCGRCHKSCTGRCWGPTENHCQTLTRTVCAEQCDGRCYGPYVSDCCHRECAGGCSGPKDTDCFACMNFNDSGACVTQCPQTFVYNPTTFQLEHNFNAKYTYGAFCVKKCPHNFVVDSSSCVRACPSSKMEVEENGIKMCKPCTDICPKACDGIGTGSLMSAQTVDSSNIDKFINCTKINGNLIFLVTGIHGDPYNAIEAIDPEKLNVFRTVREITGFLNIQSWPPNMTDFSVFSNLVTIGGRVLYSGLSLLILKQQGITSLQFQSLKEISAGNIYITDNSNLCYYHTINWTTLFSTINQRIVIRDNRKAENCTAEGMVCNHLCSSDGCWGPGPDQCLSCRRFSRGRICIESCNLYDGEFREFENGSICVECDPQCEKMEDGLLTCHGPGPDNCTKCSHFKDGPNCVEKCPDGLQGANSFIFKYADPDRECHPCHPNCTQGCNGPTSHDCIYYPWTGHSTLPQHARTPLIAAGVIGGLFILVIVGLTFAVYVRRKSIKKKRALRRFLETELVEPLTPSGTAPNQAQLRILKETELKRVKVLGSGAFGTVYKGIWVPEGETVKIPVAIKILNETTGPKANVEFMDEALIMASMDHPHLVRLLGVCLSPTIQLVTQLMPHGCLLEYVHEHKDNIGSQLLLNWCVQIAKGMMYLEERRLVHRDLAARNVLVKSPNHVKITDFGLARLLEGDEKEYNADGGKMPIKWMALECIHYRKFTHQSDVWSYGVTIWELMTFGGKPYDGIPTREIPDLLEKGERLPQPPICTIDVYMVMVKCWMIDADSRPKFKELAAEFSRMARDPQRYLVIQGDDRMKLPSPNDSKFFQNLLDEEDLEDMMDAEEYLVPQAFNIPPPIYTSRARIDSNRSEIGHSPPPAYTPMSGNQFVYRDGGFAAEQGVSVPYRAPTSTIPEAPVAQGATAEIFDDSCCNGTLRKPVAPHVQEDSSTQRYSADPTVFAPERSPRGELDEEGYMTPMRDKPKQEYLNPVEENPFVSRRKNGDLQALDNPEYHNASNGPPKAEDEYVNEPLYLNTFANTLGKAEYLKNNILSMPEKAKKAFDNPDYWNHSLPPRSTLQHPDYLQEYSTKYFYKQNGRIRPIVAENPEYLSEFSLKPGTVLPPPPYRHRNTVV
    Show/Hide
Organism
Homo sapiens, Human
Protein Classification
Enzyme
>
Kinase
>
Protein Kinase
>
TK protein kinase group
>
Tyrosine protein kinase EGFR family
Function
Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis. Required for normal cardiac muscle differentiation during embryonic development, and for postnatal cardiomyocyte proliferation. Required for normal development of the embryonic central nervous system, especially for normal neural crest cell migration and normal axon guidance. Required for mammary gland differentiation, induction of milk proteins and lactation. Acts as cell-surface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and the EGF family members BTC, EREG and HBEGF. Ligand binding triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Ligand specificity and signaling is modulated by alternative splicing, proteolytic processing, and by the formation of heterodimers with other ERBB family members, thereby creating multiple combinations of intracellular phosphotyrosines that trigger ligand- and context-specific cellular responses. Mediates phosphorylation of SHC1 and activation of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Isoform JM-A CYT-1 and isoform JM-B CYT-1 phosphorylate PIK3R1, leading to the activation of phosphatidylinositol 3-kinase and AKT1 and protect cells against apoptosis. Isoform JM-A CYT-1 and isoform JM-B CYT-1 mediate reorganization of the actin cytoskeleton and promote cell migration in response to NRG1. Isoform JM-A CYT-2 and isoform JM-B CYT-2 lack the phosphotyrosine that mediates interaction with PIK3R1, and hence do not phosphorylate PIK3R1, do not protect cells against apoptosis, and do not promote reorganization of the actin cytoskeleton and cell migration. Proteolytic processing of isoform JM-A CYT-1 and isoform JM-A CYT-2 gives rise to the corresponding soluble intracellular domains (4ICD) that translocate to the nucleus, promote nuclear import of STAT5A, activation of STAT5A, mammary epithelium differentiation, cell proliferation and activation of gene expression. The ERBB4 soluble intracellular domains (4ICD) colocalize with STAT5A at the CSN2 promoter to regulate transcription of milk proteins during lactation. The ERBB4 soluble intracellular domains can also translocate to mitochondria and promote apoptosis.
    Show/Hide
Uniprot ID
Primary ID:
Q15303

Secondarily ID:
B7ZLD7
B7ZLE2
B7ZLE3
Q2M1W1
Q59EW4
    Show/Hide
Ensembl ID
ENSG00000178568
HGNC ID
HGNC:3432
Subcellular Location
Cell membrane
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein

Protein
Cell Line
Compound

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000013 , Sf9
Compound ID Compound Name Compound Formula
CP0431426
(E)-N-[4-[(1-benzylindazol-5-yl)amino]-7-(2-methoxyethoxy)quinazolin-6-yl]-4-(dimethylamino)but-2-enamide
   Show/Hide
C31H33N7O3
 1
1
IC50 = 1 nM
   TI
   LI
   LO
   TS
CP0379991
(E)-N-[4-[(1-benzylindazol-5-yl)amino]-7-(2-methoxyethoxy)quinazolin-6-yl]-4-pyrrolidin-1-ylbut-2-enamide
   Show/Hide
C33H35N7O3
 1
1
IC50 = 2 nM
   TI
   LI
   LO
   TS
CP0464953
(E)-N-[4-(4-phenoxyanilino)pyrido[3,4-d]pyrimidin-6-yl]-4-pyrrolidin-1-ylbut-2-enamide
   Show/Hide
C27H26N6O2
 1
1
IC50 = 2 nM
   TI
   LI
   LO
   TS
CP0374476
(E)-N-[4-[(1-benzylindazol-5-yl)amino]pyrido[3,4-d]pyrimidin-6-yl]-4-(dimethylamino)but-2-enamide
   Show/Hide
C27H26N8O
 1
1
IC50 = 3 nM
   TI
   LI
   LO
   TS
CP0379990
(E)-N-[4-[(1-benzylindazol-5-yl)amino]-7-ethoxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide
   Show/Hide
C30H31N7O2
 1
1
IC50 = 3 nM
   TI
   LI
   LO
   TS
CP0379992
(E)-N-[4-[4-(benzenesulfonamido)anilino]-7-ethoxyquinazolin-6-yl]-4-pyrrolidin-1-ylbut-2-enamide
   Show/Hide
C30H32N6O4S
 1
1
IC50 = 3 nM
   TI
   LI
   LO
   TS
CP0406352
(E)-N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]pyrido[3,4-d]pyrimidin-6-yl]-4-(dimethylamino)but-2-enamide
   Show/Hide
C26H24ClFN6O2
 1
1
IC50 = 3 nM
   TI
   LI
   LO
   TS
CP0431410
(E)-N-[7-methoxy-4-(4-phenoxyanilino)quinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide
   Show/Hide
C30H31N5O3
 1
1
IC50 = 3 nM
   TI
   LI
   LO
   TS
CP0469119
(E)-N-[4-[(1-benzylindazol-5-yl)amino]-7-(2-methoxyethoxy)quinazolin-6-yl]-4-(4-methylpiperazin-1-yl)but-2-enamide
   Show/Hide
C34H38N8O3
 1
1
IC50 = 3 nM
   TI
   LI
   LO
   TS
CP0484469
(E)-4-(dimethylamino)-N-[4-(4-phenoxyanilino)pyrido[3,4-d]pyrimidin-6-yl]but-2-enamide
   Show/Hide
C25H24N6O2
 1
1
IC50 = 3 nM
   TI
   LI
   LO
   TS
CP0379993
(E)-N-[4-[(1-benzylindazol-5-yl)amino]-7-ethoxyquinazolin-6-yl]-4-(4-methylpiperazin-1-yl)but-2-enamide
   Show/Hide
C33H36N8O2
 1
1
IC50 = 4 nM
   TI
   LI
   LO
   TS
CP0380016
(E)-N-[4-[(1-benzylindazol-5-yl)amino]-7-ethoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide
   Show/Hide
C33H35N7O2
 1
1
IC50 = 4 nM
   TI
   LI
   LO
   TS
CP0431412
(E)-N-[4-[(1-benzylindazol-5-yl)amino]pyrido[3,4-d]pyrimidin-6-yl]-4-pyrrolidin-1-ylbut-2-enamide
   Show/Hide
C29H28N8O
 1
1
IC50 = 4 nM
   TI
   LI
   LO
   TS
CP0431430
(E)-4-(dimethylamino)-N-[4-[4-(pyridin-2-ylmethyl)anilino]pyrido[3,4-d]pyrimidin-6-yl]but-2-enamide
   Show/Hide
C25H25N7O
 1
1
IC50 = 4 nM
   TI
   LI
   LO
   TS
CP0432689
(E)-N-[4-[(1-benzylindazol-5-yl)amino]-7-ethoxyquinazolin-6-yl]-4-pyrrolidin-1-ylbut-2-enamide
   Show/Hide
C32H33N7O2
 1
1
IC50 = 4 nM
   TI
   LI
   LO
   TS
CP0432972
(E)-N-[4-[4-(pyridin-2-ylmethyl)anilino]pyrido[3,4-d]pyrimidin-6-yl]-4-pyrrolidin-1-ylbut-2-enamide
   Show/Hide
C27H27N7O
 1
1
IC50 = 4 nM
   TI
   LI
   LO
   TS
CP0432974
(E)-N-[4-[(1-benzylindazol-5-yl)amino]-7-ethoxyquinazolin-6-yl]-4-[(3S,5R)-3,5-dimethylpiperazin-1-yl]but-2-enamide
   Show/Hide
C34H38N8O2
 1
1
IC50 = 4 nM
   TI
   LI
   LO
   TS
CP0467073
(E)-N-[4-[(1-benzylindazol-5-yl)amino]-7-ethoxyquinazolin-6-yl]-4-[(2S,6R)-2,6-dimethylpiperazin-1-yl]but-2-enamide
   Show/Hide
C34H38N8O2
 1
1
IC50 = 4 nM
   TI
   LI
   LO
   TS
CP0467074
(E)-N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-7-ethoxyquinazolin-6-yl]-4-pyrrolidin-1-ylbut-2-enamide
   Show/Hide
C31H31ClFN5O3
 1
1
IC50 = 4 nM
   TI
   LI
   LO
   TS
CP0374477
(E)-N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]pyrido[3,4-d]pyrimidin-6-yl]-4-pyrrolidin-1-ylbut-2-enamide
   Show/Hide
C28H26ClFN6O2
 1
1
IC50 = 5 nM
   TI
   LI
   LO
   TS
CP0431408
(E)-N-[4-[(1-benzylindazol-5-yl)amino]-7-ethoxyquinazolin-6-yl]-4-[(2R,6S)-2,6-dimethylpiperidin-1-yl]but-2-enamide
   Show/Hide
C35H39N7O2
 1
1
IC50 = 5 nM
   TI
   LI
   LO
   TS
CP0374470
(E)-N-[4-[(1-benzylindazol-5-yl)amino]-7-ethoxyquinazolin-6-yl]-4-morpholin-4-ylbut-2-enamide
   Show/Hide
C32H33N7O3
 1
1
IC50 = 6 nM
   TI
   LI
   LO
   TS
CP0374474
(E)-N-[4-[(1-benzylindazol-5-yl)amino]-7-ethoxyquinazolin-6-yl]-4-[di(propan-2-yl)amino]but-2-enamide
   Show/Hide
C34H39N7O2
 1
1
IC50 = 6 nM
   TI
   LI
   LO
   TS
CP0431411
(E)-N-[4-(3-chloro-4-fluoroanilino)pyrido[3,4-d]pyrimidin-6-yl]-4-piperidin-1-ylbut-2-enamide
   Show/Hide
C22H22ClFN6O
 1
1
IC50 = 7 nM
   TI
   LI
   LO
   TS
CP0442803
(E)-N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-7-ethoxyquinazolin-6-yl]-4-(4-methylpiperazin-1-yl)but-2-enamide
   Show/Hide
C32H34ClFN6O3
 1
1
IC50 = 10 nM
   TI
   LI
   LO
   TS
CP0458760
(E)-N-[4-[[1-(benzenesulfonyl)indol-5-yl]amino]-7-ethoxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide
   Show/Hide
C30H30N6O4S
 1
1
IC50 = 10 nM
   TI
   LI
   LO
   TS
CP0406339
(E)-N-[4-[[1-(benzenesulfonyl)indol-5-yl]amino]-7-ethoxyquinazolin-6-yl]-4-pyrrolidin-1-ylbut-2-enamide
   Show/Hide
C32H32N6O4S
 1
1
IC50 = 11 nM
   TI
   LI
   LO
   TS
CP0431358
(E)-N-[7-methoxy-4-[4-(pyridin-2-ylmethyl)anilino]quinazolin-6-yl]-4-pyrrolidin-1-ylbut-2-enamide
   Show/Hide
C29H30N6O2
 1
1
IC50 = 13 nM
   TI
   LI
   LO
   TS
CP0380015
N-[7-methoxy-4-[[1-(pyridin-2-ylmethyl)indazol-5-yl]amino]quinazolin-6-yl]propanamide
   Show/Hide
C25H23N7O2
 1
1
IC50 = 15 nM
   TI
   LI
   LO
   TS
CP0406340
(E)-N-[4-[4-(benzenesulfonamido)anilino]-7-ethoxyquinazolin-6-yl]-4-morpholin-4-ylbut-2-enamide
   Show/Hide
C30H32N6O5S
 1
1
IC50 = 18 nM
   TI
   LI
   LO
   TS
CP0520421
N-[4-[(1-benzylindazol-5-yl)amino]-7-methoxyquinazolin-6-yl]propanamide
   Show/Hide
C26H24N6O2
 1
1
IC50 = 18 nM
   TI
   LI
   LO
   TS
CP0380019
N-[4-[[1-(furan-2-ylmethyl)indol-5-yl]amino]-7-methoxyquinazolin-6-yl]propanamide
   Show/Hide
C25H23N5O3
 1
1
IC50 = 22 nM
   TI
   LI
   LO
   TS
CP0380017
(E)-N-[4-[[1-(benzenesulfonyl)indol-5-yl]amino]-7-ethoxyquinazolin-6-yl]-4-morpholin-4-ylbut-2-enamide
   Show/Hide
C32H32N6O5S
 1
1
IC50 = 27 nM
   TI
   LI
   LO
   TS
CP0642885
N-(4-(3-chloro-4-fluorophenylamino)-7-(3-morpholinopropoxy)quinazolin-6-yl)acrylamide dihydrochloride
   Show/Hide
C24H27Cl3FN5O3
 1
1
IC50 = 27 nM
   TI
   LI
   LO
   TS
CP0374475
(E)-N-[4-(3-chloro-4-fluoroanilino)pyrido[3,4-d]pyrimidin-6-yl]-4-(dimethylamino)but-2-enamide
   Show/Hide
C19H18ClFN6O
 1
1
IC50 = 28 nM
   TI
   LI
   LO
   TS
CP0432690
(E)-N-[4-[4-(benzenesulfonamido)anilino]-7-ethoxyquinazolin-6-yl]-4-(4-methylpiperazin-1-yl)but-2-enamide
   Show/Hide
C31H35N7O4S
 1
1
IC50 = 29 nM
   TI
   LI
   LO
   TS
CP0432953
N-[4-[(1-benzylindol-5-yl)amino]-7-methoxyquinazolin-6-yl]propanamide
   Show/Hide
C27H25N5O2
 1
1
IC50 = 38 nM
   TI
   LI
   LO
   TS
CP0379987
N-[4-[4-(1,3-benzodioxol-5-yloxy)anilino]-7-methoxyquinazolin-6-yl]propanamide
   Show/Hide
C25H22N4O5
 1
1
IC50 = 40 nM
   TI
   LI
   LO
   TS
CP0374472
(E)-N-[7-ethoxy-4-[4-(pyridin-2-ylmethoxy)anilino]quinazolin-6-yl]-4-pyrrolidin-1-ylbut-2-enamide
   Show/Hide
C30H32N6O3
 1
1
IC50 = 41 nM
   TI
   LI
   LO
   TS
CP0374473
(E)-N-[4-(3-chloro-4-fluoroanilino)pyrido[3,4-d]pyrimidin-6-yl]-4-morpholin-4-ylbut-2-enamide
   Show/Hide
C21H20ClFN6O2
 1
1
IC50 = 43 nM
   TI
   LI
   LO
   TS
CP0476116
N-[7-methoxy-4-(4-phenoxyanilino)quinazolin-6-yl]propanamide
   Show/Hide
C24H22N4O3
 1
1
IC50 = 48 nM
   TI
   LI
   LO
   TS
CP0471252
N-[4-[[1-(benzenesulfonyl)indol-5-yl]amino]-7-methoxyquinazolin-6-yl]propanamide
   Show/Hide
C26H23N5O4S
 1
1
IC50 = 63 nM
   TI
   LI
   LO
   TS
CP0380020
N-[4-[4-(benzylamino)anilino]-7-methoxyquinazolin-6-yl]propanamide
   Show/Hide
C25H25N5O2
 1
1
IC50 = 64 nM
   TI
   LI
   LO
   TS
CP0153482
DACOMITINIB
   Show/Hide
C24H25ClFN5O2
 1
1
IC50 = 74 nM
   TI
   LI
   LO
   TS
CP0432693
N-[4-[4-[hydroxy(phenyl)methyl]anilino]-7-methoxyquinazolin-6-yl]propanamide
   Show/Hide
C25H24N4O3
 1
1
IC50 = 78 nM
   TI
   LI
   LO
   TS
CP0467071
N-[4-[(1-benzyl-2,3-dihydroindol-5-yl)amino]-7-methoxyquinazolin-6-yl]propanamide
   Show/Hide
C27H27N5O2
 1
1
IC50 = 82 nM
   TI
   LI
   LO
   TS
CP0432975
(E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-[di(propan-2-yl)amino]but-2-enamide
   Show/Hide
C25H29ClFN5O2
 1
1
IC50 = 88 nM
   TI
   LI
   LO
   TS
CP0380018
(E)-4-(4-methylpiperazin-1-yl)-N-[4-[4-(pyridin-2-ylmethyl)anilino]pyrido[3,4-d]pyrimidin-6-yl]but-2-enamide
   Show/Hide
C28H30N8O
 1
1
IC50 = 94 nM
   TI
   LI
   LO
   TS
CP0431360
(E)-N-[7-ethoxy-4-[4-(pyridin-2-ylmethoxy)anilino]quinazolin-6-yl]-4-(4-methylpiperazin-1-yl)but-2-enamide
   Show/Hide
C31H35N7O3
 1
1
IC50 = 94 nM
   TI
   LI
   LO
   TS
CP0432692
N-[7-methoxy-4-[[1-(pyridin-2-ylmethyl)indol-5-yl]amino]quinazolin-6-yl]propanamide
   Show/Hide
C26H24N6O2
 1
1
IC50 = 95 nM
   TI
   LI
   LO
   TS
CP0464950
N-[4-[4-(3-fluorophenoxy)anilino]-7-methoxyquinazolin-6-yl]propanamide
   Show/Hide
C24H21FN4O3
 1
1
IC50 = 97 nM
   TI
   LI
   LO
   TS
CP0473244
N-[7-methoxy-4-[4-(pyridin-2-ylmethoxy)anilino]quinazolin-6-yl]propanamide
   Show/Hide
C24H23N5O3
 1
1
IC50 = 108 nM
   TI
   LI
   LO
   TS
CP0227701
[(3S)-morpholin-3-yl]methyl N-[4-[[1-[(3-fluorophenyl)methyl]indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamate
   Show/Hide
C27H27FN8O3
 1
1
IC50 = 190 nM
   TI
   LI
   LO
   TS
CP0374469
N-[7-methoxy-4-[[1-(pyridin-4-ylmethyl)indol-5-yl]amino]quinazolin-6-yl]propanamide
   Show/Hide
C26H24N6O2
 1
1
IC50 = 213 nM
   TI
   LI
   LO
   TS
CP0540311
N-[7-methoxy-4-(4-pyridin-3-yloxyanilino)quinazolin-6-yl]propanamide
   Show/Hide
C23H21N5O3
 1
1
IC50 = 285 nM
   TI
   LI
   LO
   TS
CP0467076
(E)-N-[4-(3-chloro-4-fluoroanilino)pyrido[3,4-d]pyrimidin-6-yl]-4-(4-methylpiperazin-1-yl)but-2-enamide
   Show/Hide
C22H23ClFN7O
 1
1
IC50 = 302 nM
   TI
   LI
   LO
   TS
CP0431409
N-[7-methoxy-4-[[1-(pyridin-3-ylmethyl)indol-5-yl]amino]quinazolin-6-yl]propanamide
   Show/Hide
C26H24N6O2
 1
1
IC50 = 328 nM
   TI
   LI
   LO
   TS
CP0432954
N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]propanamide
   Show/Hide
C18H16ClFN4O2
 1
1
IC50 = 376 nM
   TI
   LI
   LO
   TS
CP0431424
N-[4-[4-(benzenesulfonamido)anilino]-7-methoxyquinazolin-6-yl]propanamide
   Show/Hide
C24H23N5O4S
 1
1
IC50 = 408 nM
   TI
   LI
   LO
   TS
CP0473245
N-[7-methoxy-4-[4-(pyridin-4-ylmethoxy)anilino]quinazolin-6-yl]propanamide
   Show/Hide
C24H23N5O3
 1
1
IC50 = 428 nM
   TI
   LI
   LO
   TS
CP0379989
N-[7-methoxy-4-(4-phenylmethoxyanilino)quinazolin-6-yl]propanamide
   Show/Hide
C25H24N4O3
 1
1
IC50 = 460 nM
   TI
   LI
   LO
   TS
CP0036082
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
   Show/Hide
C22H24ClFN4O3
 1
1
IC50 = 476 nM
   TI
   LI
   LO
   TS
CP0458759
N-[4-[[6-(benzenesulfonamido)pyridin-3-yl]amino]-7-methoxyquinazolin-6-yl]propanamide
   Show/Hide
C23H22N6O4S
 1
1
IC50 = 487 nM
   TI
   LI
   LO
   TS
CP0432973
N-[7-methoxy-4-[[1-(pyridin-2-ylmethyl)-2,3-dihydroindol-5-yl]amino]quinazolin-6-yl]propanamide
   Show/Hide
C26H26N6O2
 1
1
IC50 = 514 nM
   TI
   LI
   LO
   TS
CP0431425
N-[4-[4-(benzenesulfonamido)-3-fluoroanilino]-7-methoxyquinazolin-6-yl]propanamide
   Show/Hide
C24H22FN5O4S
 1
1
IC50 = 583 nM
   TI
   LI
   LO
   TS
CP0465177
N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-7-methoxyquinazolin-6-yl]propanamide
   Show/Hide
C25H22ClFN4O3
 1
1
IC50 = 636 nM
   TI
   LI
   LO
   TS
CP0432971
N-[7-methoxy-4-[4-(2-phenylethyl)anilino]quinazolin-6-yl]propanamide
   Show/Hide
C26H26N4O2
 1
1
IC50 = 653 nM
   TI
   LI
   LO
   TS
CP0379988
N-[7-methoxy-4-[4-(pyridin-2-ylmethyl)anilino]quinazolin-6-yl]propanamide
   Show/Hide
C24H23N5O2
 1
1
IC50 = 676 nM
   TI
   LI
   LO
   TS
CP0879040
5-Trifluoromethyl-2'-(3-trifluoromethyl-phenoxymethyl)-biphenyl-3-sulfonic acid [2-(3-fluoro-phenyl)-ethyl]-amide
   Show/Hide
C29H22F7NO3S
 1
1
IC50 = 4410 nM
   TI
   LI
   LO
   TS
CP0879039
5-Trifluoromethyl-4'-(3-trifluoromethyl-phenoxymethyl)-biphenyl-3-sulfonic acid [2-(3-fluoro-phenyl)-ethyl]-amide
   Show/Hide
C29H22F7NO3S
 1
1
IC50 = 5060 nM
   TI
   LI
   LO
   TS
CP0879057
N-[2-(3-Fluoro-phenyl)-ethyl]-3-thianthren-1-yl-5-trifluoromethyl-benzenesulfonamide
   Show/Hide
C27H19F4NO2S3
 1
1
IC50 = 6400 nM
   TI
   LI
   LO
   TS
CP0851720
4'-[4-(2-Methoxy-ethyl)-phenoxymethyl]-5-trifluoromethyl-biphenyl-3-sulfonic acid [2-(3-fluoro-phenyl)-ethyl]-amide
   Show/Hide
C31H29F4NO4S
 1
1
IC50 = 6430 nM
   TI
   LI
   LO
   TS
CP0139001
N-(4-fluorophenyl)-1-methyl-3-[[methyl-[2-(4-phenylphenyl)ethyl]amino]methyl]indole-5-carboxamide
   Show/Hide
C32H30FN3O
 1
1
IC50 = 7900 nM
   TI
   LI
   LO
   TS
CP0914245
3-(2,2'-bithiophen-5-yl)-N-(3-fluorophenethyl)-5-(trifluoromethyl)benzenesulfonamide
   Show/Hide
C23H17F4NO2S3
 1
1
IC50 = 8050 nM
   TI
   LI
   LO
   TS
Biochemical Assays
Compound ID Compound Name Compound Formula
CP0130523
5-(2-methylsulfonylpyrimidin-4-yl)-6-(3-phenylmethoxyphenyl)imidazo[2,1-b][1,3]thiazole
   Show/Hide
C23H18N4O3S2
 1
1 IC50 = 15.24 nM
CP0153482
DACOMITINIB
   Show/Hide
C24H25ClFN5O2
 1
1 IC50 = 83.67 nM
CP0007142
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
   Show/Hide
C29H26ClFN4O4S
 3
1 IC50 = 387 nM
2 IC50 > 1000 nM
3 Kd = 54 nM
CP0037987
N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
   Show/Hide
C22H23N3O4
 2
1 IC50 = 1130 nM
2 Kd = 230 nM
CP0036082
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
   Show/Hide
C22H24ClFN4O3
 1
1 Kd = 410 nM
Clinical Information about the Protein
Target 1 ( Erbb4 tyrosine kinase receptor (Erbb-4) )
Target Type Successful Target
Disease 3 Target-related Diseases  3
1 Non-small-cell lung cancer [ICD-11: 2C25.Y]
2 Lymphoma [ICD-11: 2A80-2A86]
3 Solid tumour/cancer [ICD-11: 2A00-2F9Z]
Approved Drug(s) 1 Approved Drug  1
1 Dacomitinib Approved
Non-small-cell lung cancer
Clinical Trial Drug(s) 2 Clinical Trial Drugs  2
1 CI-1033 Phase 2
Lymphoma
2 RG7388 Phase 3
Solid tumour/cancer
Target 2 ( HER4 messenger RNA (ERBB4 mRNA) )
Target Type Literature-reported Target